EyePoint Pharmaceuticals Revenue and Competitors

Claim your profile

Boston, MA USA

Location

#5800

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • EyePoint Pharmaceuticals's estimated annual revenue is currently $3M per year.(i)
  • EyePoint Pharmaceuticals received $60.0M in venture funding in February 2019.
  • EyePoint Pharmaceuticals's estimated revenue per employee is $17,017
  • EyePoint Pharmaceuticals's total funding is $392.9M.

Employee Data

  • EyePoint Pharmaceuticals has 174 Employees.(i)
  • EyePoint Pharmaceuticals grew their employee count by 21% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.2M1-99%N/AN/A
#2
$3.1M20233%N/AN/A
#3
$21.5M13918%$351MN/A
#4
$18M1165%$312.8MN/A
#5
$235M418-23%$340.9MN/A
#6
$2.2M3417%N/AN/A
#7
$6M40-9%$176.5MN/A
#8
$109.4M70614%N/AN/A
#9
$6.2M40233%N/AN/A
#10
$1.9M12-20%N/AN/A

EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products. As a leading provider of miniaturized, sustained-release drug delivery products, we focus on improving the lives of patients with serious eye disorders in indications with high unmet medical need. With 3 FDA-approved sustained release treatments in ophthalmology we continue to push the evolution of our Durasert Technology platform to further enhance treatments for wet age-related macular degeneration, glaucoma, osteoarthritis and other diseases.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

$392.9M

Total Funding

174

Number of Employees

$3M

Revenue (est)

21%

Employee Growth %

N/A

Valuation

N/A

Accelerator

EyePoint Pharmaceuticals News

2022-04-17 - EyePoint Pharmaceuticals to Participate in Fireside Chat at ...

WATERTOWN, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to...

2022-04-17 - EyePoint Pharmaceuticals Reports Inducement Grants Under ...

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Apr 18, 2022. Published: Apr 18, 2022. WATERTOWN, Mass., April 18,...

2022-04-17 - EyePoint Pharmaceuticals to Participate in Fireside Chat at ...

EyePoint Pharmaceuticals to Participate in Fireside Chat at the B. Riley 2022 Virtual Neuro & Ophthalmology Conference.

2021-11-19 - EyePoint Pharmaceuticals Announces Closing of $115.4 Million Public Offering

WATERTOWN, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the closing of the previously ann ...

2019-09-08 - Short Interest in Eyepoint Pharmaceuticals Inc (NASDAQ ...

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) was the target of a significant increase in short interest during the month of July. As of July 31st, ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$34M17425%$273.8M
#2
$44.9M174-6%N/A
#3
$35.4M179N/AN/A
#4
$37M1845%N/A
#5
$15M18515%N/A

EyePoint Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2011-01-20$10.8MUndisclosedRodman & Renshaw LLCArticle
2012-08-03$5.4MUndisclosedRodman & Renshaw LLCArticle
2013-07-22$10.8MUndisclosedArticle
2014-03-14$7.0MUndisclosedRA CapitalArticle
2014-10-28$25.0MUndisclosedArticle
2019-02-14$60.0MUndisclosedCR Group L.P.Article